Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan.
OBJECTIVE
To investigate the efficacy and safety of single-dose filgrastim administered 24 hours prior to chemotherapy in the prevention of topotecan-related myeloid suppression.


METHODS
No medication was given to 21 rats in group 1; 1.5 mg/m2/day topotecan was administered intraperitoneally for five days every three weeks to 21 rats in group II; a single dose of 5 microg/kg filgrastim was injected intraperitoneally 24 hours before the intraperitoneal administration of the same dose of topotecan to 21 rats in group III. After completion of six cycles of chemotherapy. the rats were decapitated and blood samples were immediately collected into citrated tubes for complete blood counts.


RESULTS
White blood cell and lymphocyte counts in the control and the filgrastim + topotecan groups were similar (p > 0.05) and significantly higher than the counts in the topotecan group (p < 0.05). There was no difference in means of neutrophil, monocyte, eosinophil, basophil and erythrocyte counts among the groups (p > 0.05).


CONCLUSIONS
Filgrastim administration prior to chemotherapy seems to be beneficial and further investigations are needed.
Ozan
H
H
Uludağ University Medical Faculty, Department of Obstetrics and Gynaecology, Bursa, Turkey.
Ozkalemkas
F
F
Ozan
U
U
Ozerkan
K
K
Bilgin
T
T
Küçükyildiz
F
F
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D019772:Topotecan / Q000633:toxicity*
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D019772:Topotecan; D000069585:Filgrastim